SCHEMBL4877285

SCHEMBL4877285

O=C(O)c1cc2c(s1)c(C1CCCCC1)c(-c1ccc3nc(-c4ccc(F)cc4)ccc3c1)n2CC(=O)N1CCC(N2CCCC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
IRAK4 Q9NWZ3 3/20 0.36
TP53 P04637 1/20 0.36
GAA P10253 2/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 1/20 0.36
CYP2D6 P10635 1/20 0.35
HRH1 P35367 1/20 0.35
ALDH1A1 P00352 3/20 0.34
KMT2A Q03164 2/20 0.34
CBX7 O95931 2/20 0.34
CDYL2 Q8N8U2 2/20 0.34
CDYL Q9Y232 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CDY1; CDY1B Q9Y6F8 1/20 0.34
CYP2C9 P11712 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PKM P14618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4876782 0.93 GAA (0.37) MAPTIRAK4TP53GAAPOLB
SCHEMBL4878071 0.93 TP53 (0.35) MAPTIRAK4TP53GAAPOLB
SCHEMBL4877463 0.91 GAA (0.36) MAPTIRAK4TP53GAAPOLB
SCHEMBL4872058 0.89 GAA (0.40) MAPTIRAK4TP53GAAPOLB
SCHEMBL2996646 0.89 GAA (0.42) IRAK4GAAPOLBTSHRCYP2D6
SCHEMBL4876422 0.89 HRH1 (0.34) GAACYP2D6HRH1ALDH1A1KMT2A
SCHEMBL4874410 0.89 TRPV4 (0.38) IRAK4GAAPOLBTSHRGRIN2B
SCHEMBL4877296 0.89 GAA (0.40) MAPTIRAK4TP53GAAPOLB
SCHEMBL4872438 0.89 TSHR (0.37) TP53GAAPOLBTSHRALDH1A1
SCHEMBL4868392 0.89 CBX7 (0.40) GAACYP2D6HRH1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 MAPT 4372/4885IRAK4 1626/4885TP53 3049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.